Valeant Pharmaceuticals International, Inc. (Johnson & Johnson), In the Matter of

Last Updated:
In the Matter of Valeant Pharmaceuticals International, Inc., a corporation
FTC Matter/File Number:

1110216

Docket Number:

C-4343

Enforcement Type:

Part 2 Consents

Case Summary

On 12/12/2011, the FTC approved orders requiring Valeant Pharmaceuticals International, Inc. to divest three drugs used to treat different skin ailments, as conditions of acquiring Ortho Dermatologics, Inc. from Johnson & Johnson, and Dermik Laboratories, Inc. from Sanofi. Under the settlements, Valeant will sell the manufacturing and marketing rights to drug products that treat acne and actinic keratosis, a pre-cancerous skin lesion, to Mylan Pharmaceuticals Inc. Valeant also will sell the marketing rights to a drug that treats fine line wrinkles to Spear Pharmaceuticals, Inc. Both settlements preserve competition and prevent higher prices that likely would have resulted from the acquisitions. (also see 1110215).